Chimeric antigen receptors that bind to SSEA4 and uses thereof
AssigneeCHO Pharma USA, Inc.
InventorLan Bo Chen
Life of this patent
Estimating the term…
Loading patent…
AssigneeCHO Pharma USA, Inc.
InventorLan Bo Chen
Estimating the term…
An isolated nucleic acid that contains a nucleotide sequence that encodes the polypeptide of SEQ ID NO: 3. The polypeptide of SEQ ID NO: 3 specifically binds to stage-specific embryonic antigen 4 (SSEA4). Also disclosed is a recombinant cell comprising the isolated nucleic acid described above, a viral vector containing the above isolated nucleic acid, and an isolated polypeptide including the sequence of SEQ ID NO: 3. Provided as well is a chimeric antigen receptor (CAR) that includes a single chain Fv having the sequence of SEQ ID NO: 3 and specifically binding to SSEA4. Moreover, a method is disclosed for treating a tumor by transducing in vitro the T cells of a subject having a tumor expressing SSEA4 with a vector that encodes the CAR, expanding the transduced T cells, and infusing the expanded transduced T cells into the subject, whereby an anti-tumor T cell response is raised.
An isolated polypeptide comprising the sequence of SEQ ID NO:
A chimeric antigen receptor, comprising a single chain Fv (scFv) that specifically binds to stage-specific embryonic antigen 4, and a first endodomain from CD3ζ or FccRIγ, wherein the scFv has the sequence of SEQ ID NO:
Dependencies are inferred from the claim text.